脂质组学分析揭示肥胖患者中肝脏脂肪酸谱改变与MASLD分期相关
这项在肥胖接受减脂手术患者中开展的病例对照研究,采用气相色谱-质谱法测定肝脏和血清脂肪酸,并按MASLD分期分为无MASLD组(n=26)、脂肪性肝病组(n=33)和代谢功能障碍相关脂肪性肝炎组(n=32),发现肝脏而非血清脂肪酸谱在MASLD患者中显著改变,且与组织病理学诊断相关。
要点
- 合并MASLD的肥胖患者肝脏C16:0、C18:1及C18:1/C18:0比值升高,C18:0及C18:0/C16:0比值降低。
- MASLD患者肝脏脂肪酸代谢相关基因表达上调,提示肝脏从头脂肪生成增强。
- 三组间脂肪酸摄入量无差异,提示肝脏脂肪酸改变非单纯由膳食脂肪酸摄入所致。
核心结论
- MASLD患者肝脏脂肪酸水平改变源于肝脏从头脂肪生成增强。
研究设计与样本
- 病例对照研究,纳入2020年1月至2021年12月在一所大学医院接受减脂手术的肥胖患者,分为无MASLD组(n=26)、脂肪性肝病组(n=33)和代谢功能障碍相关脂肪性肝炎组(n=32)。
- 采用气相色谱-质谱法测定肝脏和血清脂肪酸水平,用经验证的食物频率问卷评估营养状况,用逆转录定量聚合酶链反应分析脂肪酸代谢相关基因的肝脏表达。
主要发现
- 与无MASLD患者相比,MASLD患者肝脏而非血清脂肪酸谱显著改变。
- 三组间脂肪酸摄入量无差异。
- MASLD患者C16:0、C18:1及C18:1/C18:0比值较高,C18:0水平及C18:0/C16:0比值较低,三组间差异显著。
- 肝脏脂肪酸水平及比值与组织病理学诊断及其他MASLD相关参数相关。
- MASLD患者脂肪酸代谢相关基因表达上调。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by the intracellular lipid accumulation in hepatocytes. Excess caloric intake and high-fat diets are considered to significantly contribute to MASLD development. OBJECTIVE: To evaluate the hepatic and serum fatty acid (FA) composition in patients with different stages of MASLD, and their relationship with FA dietary intake and MASLD-related risk factors. METHODS: This was a case-control study in patients with obesity undergoing bariatric surgery at a university hospital between January 2020 and December 2021. Participants were distributed in 3 groups: no MASLD (n = 26), steatotic liver disease (n = 33), and metabolic dysfunction-associated steatohepatitis (n = 32). Hepatic and serum FA levels were determined by gas chromatography-mass spectrometry. Nutritional status was evaluated using validated food frequency questionnaires. The hepatic expression of genes involved in FA metabolism was analyzed by reverse transcription quantitative polymerase chain reaction. RESULTS: The hepatic, but not serum, FA profiles were significantly altered in patients with MASLD compared with those without MASLD. No differences were observed in FA intake between the groups. Levels of C16:0, C18:1, and the C18:1/C18:0 ratio were higher, while C18:0 levels and C18:0/C16:0 ratio were lower in patients with MASLD, being significantly different between the 3 groups. Hepatic FA levels and ratios correlated with histopathological diagnosis and other MASLD-related parameters. The expression of genes involved in the FA metabolism was upregulated in patients with MASLD. CONCLUSION: Alterations in hepatic FA levels in MASLD patients were due to enhancement of de novo lipogenesis in the liver.
引用
- Núñez-Sánchez MÁ, Martínez-Sánchez MA, Martínez-Montoro JI, et al. Lipidomic Analysis Reveals Alterations in Hepatic FA Profile Associated With MASLD Stage in Patients With Obesity. J Clin Endocrinol Metab. 2024. PMID: 38217869. doi:10.1210/clinem/dgae028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。